| Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
Factor | UOR (95% CI) | P value | AOR (95% CI) | P value |
Sex of child | Â | 0.004* | Â | 0.041* |
 Male | ref |  |  |  |
 Female | 2.52 1.35–4.67 |  | 2.51 1.04–6.07 |  |
Age category | Â | 0.342 | Â | 0.138 |
 < 5 years | 1.72 0.57–5.24 |  | 2.18 0.23–20.89 |  |
 5 to < 10 years | 1.57 0.78 –3.17 |  | 2.84 1.01–8.05 |  |
 10 to 15 years | ref |  | ref |  |
CD4+ Immune suppression status at study recruitment |  | < 0.001* |  | < 0.001* |
 Severe | 9.03 3.08–26.51 |  | 24.93 4.92–126.31 |  |
 Advanced | 7.97 2.03–31.31 |  | 9.2 1.27–66.48 |  |
 Mild | 3.65 1.35–9.9 |  | 3.75 0.91–15.4 |  |
 None | ref |  | ref |  |
TB treatment in the past | Â | 0.122 | Â | 0.006* |
 No | ref |  | ref |  |
 Yes | 1.67 0.87–3.18 |  | 4.95 1.58–15.5 |  |
Current Drug | Â | 0.231 | Â | 0.005* |
 Efavirenz based | ref |  | ref |  |
 Nevirapine based | 1.79 0.9 – 3.52 |  | 7.93 2.26–27.86 |  |
 Second line drug | 0.86 0.15–4.86 |  | 1.02 0.09–11.8 |  |
Pill count rate | Â | 0.012* | Â | 0.264 |
 Good adherence | ref |  | ref |  |
 Fair adherence | 0.3 0.1–0.93 |  | 0.43 0.11 – 1.69 |  |
 Poor adherence | 1.93 0.92–4.03 |  | 1.65 0.54 – 5.01 |  |